A
Ascendis Pharma A/S (ASND)
216.95
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
216.95
0.00 (0.00%)
Ascendis Pharma A/S Yevropa, Qo'shma Shtatlar va xalqaro miqyosda tibbiy ehtiyojlarni qondirish uchun TransCon asosidagi terapiyalarni ishlab chiqishga qaratilgan biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniya o'sish gormoni etishmovchiligi bo'lgan bolalarni davolash uchun SKYTROFA; va surunkali gipoparatiroidizm bilan og'rigan kattalarni davolash uchun kuniga bir marta ter underiga yuboriladigan YORVIPATHni taklif etadi. Shuningdek, u klinik rivojlanish bosqichidagi uchta mustaqil endokrinologiya noyob kasalliklari mahsulot nomzodlarining portfelini ishlab chiqmoqda, shuningdek, onkologiya terapevtik nomzodlarini ilgari surishga qaratilgan. Kompaniya 2006 yilda tashkil etilgan va Daniyaning Hellerup shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
| Mr. Chad Fugure | Vice President of Investor Relations |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-17 | 6-K | d95087d6k.htm |
| 2026-03-16 | 6-K | d108415d6k.htm |
| 2026-03-11 | 6-K | d116249d6k.htm |
| 2026-03-02 | 6-K | d116890d6k.htm |
| 2026-01-14 | 6-K | d86096d6k.htm |
| 2026-01-12 | 6-K | d13397d6k.htm |
| 2026-01-09 | 6-K | d27768d6k.htm |
| 2025-12-30 | 6-K | d214993d6k.htm |
| 2025-12-10 | 6-K | d65335d6k.htm |
| 2025-11-12 | 6-K | d23481d6k.htm |